RedHill Biopharma Announced Results From New In Vivo Studies Of Opaganib For Gastrointestinal Acute Radiation Syndrome, Undertaken As Part Of The U.S. Government's Radiation And Nuclear Countermeasures Program Contract That Further Confirms Opaganib's Protective Activity In Animal Models

• Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident
• There are currently no known approved therapies for gastrointestinal acute radiation syndrome (GI-ARS)
• Positive results from new in vivo studies of opaganib as a treatment for GI-ARS, undertaken as part of the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP) product pipeline development contract, further confirm opaganib's protective activity
• Discussions now ongoing with the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID), which leads the RNCP, regarding plans for the next phase of development along the U.S. Food and Drug Administration's (FDA) Animal Rule pathway to approval